Bako, Emarjola
Daiichi Sankyo (United States)
2 papers on CoChatORCID 0009-0002-1239-170X
Most cited papers
- Verified
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 178
- Verified
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Siena, S., Di Bartolomeo, M., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2020) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 54
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free